Lead Product(s) : Eluxadoline
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval from USFDA for Eluxadoline Tablets, 75 mg and 100 mg
Details : Viberzi-Generic (eluxadoline) is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhea.
Product Name : Viberzi-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Eluxadoline
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
